ObsEva SA (OBSV) is a biotechnology firm that focuses on the development and commercialization of innovative therapies to improve reproductive health in women. In the pre-market session today, the company stock has soared 34.52 percent to $3.39.
What Does The Company Do:
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ObsEva has established an advanced clinical pipeline as well as the development of treatments for uterine fibroids, endometriosis, and preterm labor through strategic licensing, a disciplined drug development plan, and sustained in-company investment.
Read More
- What does Guardion Health Sciences (GHSI) Stock hold for Investors in 2021?
- Marathon Patent Group (MARA) to stay in action aligned with the Bitcoin Market
Recent Updates:
The company released several important updates to its Yselty program recently. These include the sending of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). MAA is essential to the marketing of the product during drug development in the EU and its validation indicates the start of the review process.
The company has attached the Phase 3 PRIMROSE 1 study and PRIMROSE 2 data with the Yselty MAA for uterine fibroids indication. Yselty doses of 100 mg or 200 mg, with and without hormonal add-back-therapy, or placebo were given to uterine fibroids patients with heavy menstrual bleeding (HMB).
ObsEva also shared that clinical development programs associated with endometriosis are a priority for them. Also in the EU, the EDELWEISS 3 trial is progressing according to plan, with primary endpoints scheduled to be available by the end of the year.
